Business Wire

Sevan Multi-Site Solutions Attracts $17.5 Million Investment to Support Continued Growth

10.12.2019 17:00:00 EET | Business Wire | Press release

Share

Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in data analytics, surveys, design, program management and construction services, today announced they have closed a $17.5 million Series A funding round led by ABS Capital Partners, a leading late-stage growth company investor. The funding will be used to expand business offerings, develop new technology and strengthen the company to ensure continued growth and scalability.

“In just over eight years, Sevan has established our reputation as a go-to multi-site program management firm and industry expert,” said Jim Evans, President and CEO of Sevan. “ABS Capital will be a terrific partner in our journey ahead. Their experienced people, culture and deep understanding of technology investments will accelerate our growth. We are delighted to continue to deliver excellence to great clients, and together we will all grow!”

Founded in 2011, Sevan helps clients develop, refresh and update their portfolio of sites. Large public competitors are not typically focused on the multi-site market, and smaller companies are unable to compete with the breadth and quality of services Sevan provides.

There is an increased need to routinely renovate and manage facility operations across broad geographies. Global organizations are devoting more time and capital to maintain and improve existing sites rather than build new ones. Rebrands, new product introductions, joint ventures creating a store within a store and new technology enabling self-service automation are all current drivers of renovation programs.

As a result of the minority investment by ABS Capital Partners, Managing General Partner Phil Clough will join the Sevan board of directors.

“We were impressed by Sevan’s national presence, strong reputation, comprehensive suite of services and technology enablement,” Clough said. “ABS Capital, having successfully invested in a significant number of business services companies over the years, recognizes Sevan’s strong growth as a key indicator of future success.”

This is the first round of institutional capital raised by Sevan. Current customers consist of more than 40 leading corporations across thousands of locations and include McDonald’s, Walgreens, Chipotle, BP, Starbucks, 7-Eleven, DaVita, HCA Healthcare and Walmart.

In 2019, Sevan ranked #713 on the Inc. 5000 list of the nation’s fastest-growing private companies. In October 2018, Sevan was named one of the 100 Best Medium Workplaces by Great Place to Work® and FORTUNE, ranking #29 on the list. Sevan has been recognized as an Employee-Rated Great Place to Work for six consecutive years.

Sevan is a 500-person project management firm headquartered in Downers Grove, Illinois, with an international office in London.

About Sevan

Sevan Multi-Site Solutions, Inc. (Sevan)’s vision is to be the best in the world at delivering data analytics, virtual tours, surveys, design, program management and construction services to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands—including 7-Eleven, AAFES, Albertsons, BP, Bento Box, Chipotle, DaVita, HCA Healthcare, Hallmark, Kroger, McDonald’s, Marathon, Office Depot, Starbucks, Sunoco, Walgreens Boots Alliance and Walmart. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes new builds, rebuilds, remodels and renovations. The company’s expertise spans numerous market sectors including banking, fuel and convenience store, government, restaurant, grocery, retail, healthcare, housing and hospitality industries. For more information, visit www.sevansolutions.com .

About ABS Capital Partners

For nearly 30 years, ABS Capital has been investing in later-stage growth companies, helping CEOs capitalize on new opportunities and navigate unforeseen obstacles – while never losing sight of the ultimate goal of achieving lasting excellence. Our partners have decades of experience as C-level executives, investment bankers, and investors in the industries in which we invest: business and tech-enabled services and health care. This combination of experience and expertise means we have a laser-focus on the specific needs growth companies face as they look to get to the next level. By helping to transform over 125 companies through their most important stage of development, ABS continues to help unleash the potential for lasting growth. ABS Capital Partners. Here, we grow. For more information, visit www.abscapital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hafsa Mahmood
Manager, Marketing & Communications
Phone: 312.285.0590
Email: hafsa.mahmood@sevansolutions.com
Website: www.sevansolutions.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye